Polypeptide With Localisation/Targeting Motif TRIZ Cases

Targeted CAR T cells eliminate alloreactive T cells via immune checkpoint markers, preventing graft versus host disease without broad immunosuppression.

Fusion proteins with fluorescent partners enable real-time monitoring of heterologous polypeptide expression in host cells.

TALE-based cytosine base editors enable efficient C-to-T conversions in plant chloroplasts and mitochondria without guide RNA delivery barriers.

Co-expressing membrane-bound IL-15 with CD8 polypeptides sustains T cell persistence and cytotoxic activity within the tumor microenvironment.

Engineered iPSCs expressing rearranged gamma-delta TCRs generate universal immune cells that eliminate graft-versus-host disease risks from HLA mismatches.

Inhibitory chimeric antigen receptors bind mural cells to suppress immune activity against the blood brain barrier.

Engineered T cells express a chimeric alloantibody receptor that eliminates B cells producing anti-Rh antibodies, preventing hemolytic disease of the newborn.

Chromatographic purification removes glycosylated impurities from recombinant insulin glargine produced in yeast.

Replacing complex chromosome banding with calreticulin detection simplifies genomic stability evaluation while maintaining accuracy for living cell cultures.

Self-replicating RNA vectors encode chimeric antigen receptors to drive robust protein expression in immune competent cells.

Adjustable walking beam rails and a lateral pusher transfer sand molds between stations of differing heights, resolving installation flexibility constraints.

Bicistronic iCAR and aCAR constructs in CD4+ and CD8+ cells reduce off-tumor toxicity by balancing activating signals with inhibitory feedback.

A virus-like particle displays proteins using a peptide tag and binding protein pair that spontaneously form covalent bonds.

CRISPR-Cas9 edits T cells to remove HLA-A and HLA-B genes, enabling universal allogeneic CAR-T production without graft-versus-host disease risk.

Plant-produced anti-EGFR antibodies use specific glycosylation patterns and Fc mutations to enhance ADCC and CDC activities against cancer cells.

Anti-CD5 antibody drug conjugates deplete CD5+ cells to promote acceptance of CAR-expressing immune cells without lymphodepleting chemotherapy side effects.

Chimeric stimulatory receptors reduce graft rejection by eliminating specific genes while preserving environmental stimulus responsiveness.

Peptides derived from intermediate filaments stimulate pro-inflammatory cytokine secretion and induce cell death in eukaryotic cells.

Nucleic acid molecules encoding HCV antigens utilize optimized codon usage to enhance protein expression and immune response generation.

A DNA vaccine encoding inactive hTERT stimulates broad CD4 and CD8 T-cell responses.

Segmented chimeric antigen receptors target B7H3 to overcome inadequate tumor therapy reliability.

Engineered Type I CRISPR-Cas effector complexes utilize Cas8-FokI fusion proteins to enable programmable DNA targeting.

Fusing SARS-CoV-2 antigens to IgG1 Fc fragments overcomes weak immune responses by enhancing antigen presentation and stability.

Ribose Binding Protein fusion tags enhance protein production yield by improving solubility and stability, enabling purification via cleavage sites.

Non-viral CAR-NK cells paired with bispecific antigen-binding molecules target tumor antigens and NK receptors, reducing treatment-related toxicity.

Polypeptide steric shields block antibody binding sites in normal tissue, reducing side effects while enabling targeted therapy at diseased sites.

An engineered receptor uses an antibody fragment to stabilize the Notch negative regulatory region, resolving low precision in mechanical signaling.

Combining a SIRPα-Fc polypeptide with chemotherapy agents overcomes CD47-mediated immune evasion, significantly increasing response rates in gastric cancer.

MicroRNA-adapted shRNA molecules reduce endogenous T cell receptor expression in genetically-modified immune cells, preventing graft-versus-host disease.

An ApoE peptide bridges the enzyme across the blood-brain barrier via receptor-mediated transcytosis.

Modified chimeric antigen receptor hinge and transmembrane domains enhance tumor cell killing while maintaining in vivo persistence.

Membrane-bound hyaluronidase on retroviral particles merges enzyme activity with viral delivery, resolving separate dispersion of co-administered biologics.

Anti-CLL-1 CAR constructs resolve efficacy complexity trade-offs by enabling precise targeting of leukemia cells.

A compound protease enables programmable protein circuits that regulate cellular behaviors without genomic integration.

Segmented NPP1 catalytic domains fused to targeting moieties inhibit arterial calcification by enhancing local pyrophosphate solubilization.

Engineered T cell receptors recognize mutant RET peptides to direct cytotoxic activity against cancer cells harboring the M918T alteration.

A secretion signal peptide fused with a cleavage inhibition sequence enables efficient intracellular protein transduction.

KIF5B-RET fusion protein serves as a specific diagnostic marker for lung adenocarcinoma detection.

Peptidic PKCζ inhibitors redistribute occludin to open tight junctions, resolving toxicity and narrow therapeutic windows in mucosal drug delivery.

Tat-CrmA fusion protein delivers anti-apoptotic cargo into cells, avoiding gene transfer safety risks.

Engineered extracellular vesicles use non-covalent syndecan-syntenin binding to encapsulate therapeutic polypeptides and targeting signals.

Engineered chimeric antigen receptors target TAG-72-expressing cancers, activating T cells to kill tumor cells via dual-binding safety controls.

Engineered chloride channel receptors hyperpolarize peripheral nerves, blocking pain signals without causing drug tolerance or dependence.

GluN2A-derived peptides disrupt zinc transporter 1 interactions to restore NMDA receptor function for schizophrenia treatment.

Anti-idiotype antibodies target anti-CD19 antibody moieties on CAR T cells, resolving low specificity and affinity issues in detection and stimulation methods.

A B2M/FcRn fusion protein in immunodeficient animals reduces graft-versus-host disease while maintaining IgG levels for reliable therapeutic studies.

Targeted chimeric proteins deliver IL-12 to tumor sites, enhancing IFN-gamma secretion while reducing systemic toxicity.

Replacing scFv with single-domain antibodies prevents membrane aggregation and reduces immunogenicity in CAR-T therapies.

CoStAR constructs combine CD3zeta and CD28 signals to overcome limited tumor costimulation, driving robust T-cell expansion.

Novel antibodies and BCMA-targeting CARs enhance therapeutic efficacy against multiple myeloma by improving binding affinity and specificity.